Developing and validating a human laboratory model to screen medications for smoking cessation.
about
Effects of experimental negative affect manipulations on ad libitum smoking: a meta-analysisAnticipation of smoking sufficiently dampens stress reactivity in nicotine-deprived smokers.How can we use our knowledge of alcohol-tobacco interactions to reduce alcohol use?Dissociated effects of anticipating smoking versus monetary reward in the caudate as a function of smoking abstinence.Anxiety sensitivity as an amplifier of subjective and behavioral tobacco abstinence effects.Weak ventral striatal responses to monetary outcomes predict an unwillingness to resist cigarette smoking.A translational investigation targeting stress-reactivity and prefrontal cognitive control with guanfacine for smoking cessationTranslational Research on Nicotine Dependence.Resisting the urge to smoke and craving during a smoking quit attempt on varenicline: results from a pilot fMRI study.Socioeconomic status and the reward value of smoking following tobacco abstinence: a laboratory study.Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal.Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.Psychological symptoms, smoking lapse behavior, and the mediating effects of nicotine withdrawal symptoms: A laboratory study.Anhedonia and the relative reward value of drug and nondrug reinforcers in cigarette smokers.Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers.Transcranial Direct Current Brain Stimulation Increases Ability to Resist SmokingCurrent insights into the mechanisms and development of treatments for heavy drinking cigarette smokersBehavioral economic analysis of cue-elicited craving for tobacco: a virtual reality studyEmerging Pharmacologic Treatments for Adolescent Substance Use: Challenges and New Directions.An efficient early phase 2 procedure to screen medications for efficacy in smoking cessation.Metabotropic glutamate receptor 5 as a potential target for smoking cessation.An overview of alcohol and tobacco/nicotine interactions in the human laboratory.Relationship between negative affect and smoking topography in heavy drinking smokers.Second Generation Electronic Nicotine Delivery System Vape Pen Exposure Generalizes as a Smoking Cue.Predictors of smoking lapse in a human laboratory paradigm.Effect of doxazosin on stress reactivity and the ability to resist smoking.Self-control depletion and nicotine deprivation as precipitants of smoking cessation failure: A human laboratory model.Toward a laboratory model for psychotherapeutic treatment screening: Implementation intentions and incentives for abstinence in an analog of smoking relapse.Smoking environment cues reduce ability to resist smoking as measured by a delay to smoking task.Reduction of smoking urges with intranasal insulin: a randomized, crossover, placebo-controlled clinical trial.Guanfacine alters the effect of stress and smoking on heart rate variability in regular daily smokers.Evaluating Point of Sale Tobacco Marketing Using Behavioral Laboratory Methods.
P2860
Q27315099-1B1A6EDF-B0BD-45E8-A476-0EFAF3C4F9B6Q30392279-2B70EB41-E628-4E57-9161-6E006508FA18Q30441131-ECD79529-BF0F-4766-9A53-EEF80C52CB80Q33632525-5439C6E0-0D86-4D53-A3E4-5A63378891CDQ34021889-BACCD71B-01D5-4F33-BEAA-48A5F7CACB7EQ34422430-A1CC03CE-53BA-4B71-B354-3CA2DACD4961Q34454236-552899FF-4096-4B72-80C7-39A9FC4D4266Q34513939-7371EDED-5FB5-4646-B17F-5BD98B9181ABQ34591568-320E97C3-71A8-4913-8815-AA7F83DC9361Q34736710-BAEB9C34-8DBC-4DCE-80D0-57EB7CA6176AQ34870758-618E6F22-803A-4BF1-B3AF-68083307567DQ35195302-D6828CDA-4A03-4F99-86E5-42F72B28FE25Q35532120-365C4004-0163-44C8-B21F-172C58CDCBB7Q35543043-88C2A151-D186-4529-AD03-4D764D9F62E6Q35689017-79EB0E5C-64C8-4EBD-93B2-2BFEAB57733EQ36680075-703D6BEC-DFCD-44AD-80BC-8F1FB5EEFA35Q36877440-7EC9052D-8A59-43C2-99AA-8A15C75763E8Q37024795-3EA4AA21-2A44-45BE-984B-0FBBDC25C3A0Q37200944-8F88F8A6-8FF1-4007-B4F3-370A5B2E561CQ37543473-E214E99D-794F-4982-A4F7-9AE7874345C6Q38795082-94E35736-1DBB-4DBA-A911-7CBF0016D394Q38839642-52273FDA-51D3-4509-92E9-8A4F3B6C531DQ38860859-5FAF1F7F-3296-43AD-BF06-EC7E2BAF9613Q39023725-7C50AF62-EBF7-4A1C-B135-8D7E696C46B5Q39255477-F77DB094-E81B-4648-B52C-9E4F73AAC406Q40229079-A8C5876E-39FA-458B-9963-6D7B1A34A913Q45055476-5D6097D9-2BB4-424B-BF66-0265EA898CD8Q45070428-40620F8F-086E-4D9E-8D61-FBC34ADF7091Q47375380-D37754B5-0DE9-4403-ADC8-015DFB843A79Q47975121-FE8D681E-1F81-4244-9390-A28DE399B3CBQ48036117-740CA65C-756C-4351-B397-C04500C4FD24Q55408402-5606DF84-86D0-4A74-9124-D4BE4BDE9F18
P2860
Developing and validating a human laboratory model to screen medications for smoking cessation.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Developing and validating a hu ...... cations for smoking cessation.
@ast
Developing and validating a hu ...... cations for smoking cessation.
@en
type
label
Developing and validating a hu ...... cations for smoking cessation.
@ast
Developing and validating a hu ...... cations for smoking cessation.
@en
prefLabel
Developing and validating a hu ...... cations for smoking cessation.
@ast
Developing and validating a hu ...... cations for smoking cessation.
@en
P2093
P2860
P356
P1476
Developing and validating a hu ...... cations for smoking cessation.
@en
P2093
Andrea H Weinberger
Jeanette Tetrault
Sabrina Coppola
Sherry A McKee
P2860
P304
P356
10.1093/NTR/NTS090
P577
2012-04-06T00:00:00Z